<DOC>
	<DOCNO>NCT02248428</DOCNO>
	<brief_summary>Due economic reason , thalidomide still widely use first line drug Multiple Myeloma patient China . However , efficacy CTd still low therapeutic regimen new drug . Clarithromycin may partly efficacy association steroid thalidomide Multiple Myeloma patient . This multicenter , randomize , phase 3 clinical trial propose explore whether clarithromycin could potentiate responsiveness CTd ( Cyclophosphamide , Thalidomide Dexamethasone ) regimen Newly Diagnosed Multiple Myeloma patient . The trial also evaluate side effect cause combination drug .</brief_summary>
	<brief_title>Clarithromycin Plus CTd Regimen Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>This phase III , randomize control trial enroll 130 ( 65 arm ) newly diagnose patient active disease 4 medical center East China . The participant randomly equally select receive BiCTd regimen arm CTd regimen arm . The treatment consist eight induction consolidation therapy follow maintenance therapy . BiCTd ( Clarithromycin , Cyclophosphamide , Thalidomide Dexamethasone ) regimen arm： Induction consolidation Phase : All patient also receive aspirin 100mg PO QD receive BiCTd . Aspirin continue maintenance . Clarithromycin 500 mg orally daily day 1-28 , thalidomide 100-200mg orally day d1-28 , dexamethasone 40 mg orally day 1,8,15,22 , cyclophosphamide 300 mg/m^2 intravenously day 1-3 . Eight Cycles repeat every 28 day . If efficacy &lt; PR 4 cycle induction， disease progression anytime，patients quit . Maintenance Therapy : Patients complete induction consolidation regimen could start maintenance therapy follow : Maintenance CP ( cyclophosphamide 200 mg orally day 1-14 prednisone 30mg twice daily orally day 1-7 , repeat every 28 day ) regimen disease progression . CTd regimen arm： Induction consolidation Phase : All patient also receive aspirin 100mg PO QD receive CTd . Aspirin continue maintenance . Thalidomide 100-200mg orally day d1-28 , dexamethasone 40 mg orally day 1,8,15,22 , cyclophosphamide 300 mg/m^2 intravenously day 1-3 . Eight Cycles repeat every 28 day . If efficacy &lt; PR 4 cycle induction， disease progression anytime，patients quit . If reduction serum urine M protein next cycle，patients may cross BiCTd regimen . Maintenance Therapy : Patients complete induction consolidation regimen could start maintenance therapy follow : Maintenance CP ( cyclophosphamide 200 mg orally day 1-14 prednisone 30mg twice daily orally day 1-7 , repeat every 28 day ) regimen disease progression Then , patient follow 24 month chemotherapy . The investigator record laboratory clinical investigation assess response different point study . We also assess adverse event ( AEs ) , grade accord NCI-Common Toxicity Criteria Adverse Effects ( CTCAE ) Version 4.0.Response category base International Myeloma Working Group uniform response criterion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Signed informed consent form Able adhere study visit schedule protocol requirement Diagnosed active multiple myeloma Previously untreated Karnofsky performance status ( KPS ) ≥50（KPS &lt; 50 allow related bony disease） New York Heart Association ( NYHA ) functional ≤class III Hypersensitivity clarithromycin excipients , erythromycin , macrolide antibiotic ; Concomitant administration cisapride , pimozide , astemizole , terfenadine , ergotamine dihydroergotamine , simvastatin , lovastatin , atorvastatin ; A history cholestatic jaundice/hepatic dysfunction associate prior use clarithromycin . Impaired renal function , Creatinine ≥221umol/L； Pregnant breast feeding female . Any condition place subject unacceptable risk he/she participate study confounds ability interpret data study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>CTd</keyword>
</DOC>